Mylan blocks Apotex paroxetine plans
This article was originally published in Scrip
Executive Summary
Mylan said it has obtained a temporary order from a US federal court blocking Apotex from launching a generic of GlaxoSmithKline's Paxil CR (paroxetine extended-release tablets), in a lawsuit that accuses the brand-name drug maker and Apotex of seeking to bring an authorised generic to the US market in breach of a deal with GSK. Mylan claims it has the sole rights to market generic Paxil CR under an exclusive patent licence and settlement agreement with GSK.